Academics at Royal Holloway have developed a new genetic medicine that has been given the go ahead by the U.S Food and Drug Association (FDA) to be prescribed globally to a subset of patients with Duchenne muscular dystrophy (DMD), a rare genetic disease that causes muscle weakness and wasting.
Read More
Health Rss 